Sun Pharma to buy Dusa for $230 million #pharmaceutical #marketing

Posted On Jun 25 2017 by

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …


Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #leading #pharmaceutical

Posted On Jun 25 2017 by

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …


India s Sun Pharma Gets U #akela #pharma #inc

Posted On Jun 15 2017 by

#sun pharma # India‚Äôs Sun Pharma Gets U.S. Subpoena Over Generic Drugs Pricing The U.S. Department of Justice (DoJ) has subpoenaed India s largest drugmaker Sun Pharmaceutical Industries Ltd seeking information about the pricing and marketing of the generic drugs it sells in the United States, the company said on Saturday. The DoJ s antitrust division has also asked Sun Pharma s U.S. unit for documents related to employee and corporate records and communications with competitors. The subpoena comes amid a wider probe by U.S. regulators into steep increases in the prices of generic medicines in recent years. For more …


Sun Pharma buys URL generic biz from Takeda #pharmaceutical #manufacturing #magazine

Posted On Jun 13 2017 by

#url pharma # Sun Pharma buys URL generic biz from Takeda In its second acquisition in a little over a month, Sun Pharma has acquired URL generic business from Japanese drug-maker Takeda for an undisclosed amount. Sun s wholly-owned subsidiary in the US, Caraco Pharmaceutical Laboratories, has entered into a definitive agreement with Takeda Pharmaceuticals USA (a wholly-owned subsidiary of Takeda), to buy the URL Pharma generic business, Sun said. URL Pharma Inc, formerly a privately held Philadelphia-based pharmaceutical company, had been acquired by Takeda America Holdings in June 2012 for $ 800 million. In fact, early last month, Sun …


Sun Pharma to buy Dusa for $230 million #top #20 #pharma

Posted On Jun 13 2017 by

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …


Sun joins dermatology rush with $230M DUSA buyout #global #pharmaceutical #industry

Posted On Jun 12 2017 by

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …


Sun Pharmaceutical Industries Ltd #top #biotech #companies #2013

Posted On Jun 11 2017 by

#sun pharma products # Sun Pharmaceutical Industries Ltd. Albumin Human This medication is derived from human plasma, used to treat shock as a result of blood loss in the body (hypovolemia), burns, low protein levels (hypoproteinemia) due to surgery or liver failure, adult respiratory distress syndrome, dialysis, and as an additional medicine in bypass surgery. It increases blood plasma volume or serum albumin levels. Alendronate This medication is a bisphosphonate, primarily used for prevention and treatment of osteoporosis in men and postmenopausal women. It is also used for Paget’s disease and osteoporosis caused by steroid treatment. It reduces the amount …


Sun Pharmaceuticals to sell some low priority Ranbaxy brands – The Economic Times #pharma #engineering

Posted On Jun 11 2017 by

#sun pharma products # Sun Pharmaceuticals to sell some low priority Ranbaxy brands MUMBAI: Drug maker Sun Pharmaceuticals has put on the block a bundle of Ranbaxy brands which are low priority in its domestic market strategy or which may overlap with its own products, top industry executives said. The country’s largest drug maker completed acquisition of Ranbaxy last year from its Japanese owner, Daiichi Sankyo. as part of a $4 billion all-stock deal. The Ranbaxy brands that Sun is looking to sell rake in about Rs 115 crore in annual sales and the company is expecting a valuation of …


Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #generic #pharmaceutical

Posted On May 28 2017 by

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …


Sun joins dermatology rush with $230M DUSA buyout #pharmaceutical #marketing #jobs

Posted On May 28 2017 by

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …